AI assistant
MCCORMICK & CO INC — Director's Dealing 2021
Sep 10, 2021
30330_dirs_2021-09-10_136ad67a-5bbb-4013-bd91-c732e7c926c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: MCCORMICK & CO INC (MKC)
CIK: 0000063754
Period of Report: 2021-08-31
Reporting Person: Repas Gregory (V.P.& Controller)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock - Voting | 890 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options - Right to Buy | $52.975 | 2028-03-27 | Common Stock - Voting (1582) | Direct | |
| Options - Right to Buy | $73.695 | 2029-03-27 | Common Stock - Voting (3622) | Direct | |
| Options - Right to Buy | $69.31 | 2030-04-01 | Common Stock - Voting (2452) | Direct | |
| Options - Right to Buy | $89.16 | 2031-03-31 | Common Stock - Voting (1907) | Direct | |
| Options - Right to Buy | $93.49 | Common Stock - Voting (14902) | Direct | ||
| Restricted Stock Units | $0 | 2022-03-27 | Common Stock - Voting (234) | Direct | |
| Restricted Stock Units | $0 | 2023-04-01 | Common Stock - Voting (324) | Direct | |
| Restricted Stock Units | $0 | 2024-03-31 | Common Stock - Voting (405) | Direct |
Footnotes
F1: The option grant becomes exercisable in thirds of each of the first three (3) grant anniversaries.
F2: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2020, March 15, 2021 and March 15, 2022
F3: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2021, March 15, 2022 and March 15, 2023.
F4: The Restricted Stock Units vest in thirds over a threeyear period beginning March 15, 2022, March 15, 2023 and March 15, 2024.
F5: The option grant was granted on November 30, 2020 and vests after the third anniversary date and is only exercisable if certain stock price performance requirements are met. The performance requirements are an increase in the common stock non-voting price of 60% for 1/3 of the options, an increase in the common stock non-voting price of 80% for 1/3 of the options, and an increase in the common stock non-voting price of 100% for 1/3 of the options, in each case within five years of the grant date. Both the vesting date and perfomance requirements must be met for the portion of the grant to become exercisable.